Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | AGXT | P21549 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP12 | P39900 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31085527 | 0.82 | IDO1 (0.40) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL3309883 | 0.82 | IDO1 (0.40) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL29471352 | 0.81 | CA3 (0.44) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL1561523 | 0.81 | CA3 (0.44) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL4316095 | 0.80 | IDO1 (0.54) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL19513345 | 0.80 | GRM5 (0.40) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL93024 | 0.80 | IDO1 (0.54) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL7700255 | 0.79 | CA3 (0.46) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL5252643 | 0.79 | MPO (0.49) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL29825244 | 0.78 | MAPT (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 504 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3398950-B1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE EGFR AND MUTATED EGFR | PRECEDO PHARMACEUTICALS CO LTD (CN) | 2021-08-11 | — | — | EP | claimed |
| US-10781214-B2 | Kinase inhibitor against wild-type and mutant EGFR | PRECEDO PHARMACEUTICALS CO., LTD. (CN) | 2020-09-22 | — | — | US | claimed |
| CN-111303179-A | Synthesis of norcantharidin carboxylic acid difluoro benzyl ester and anti-tumor application thereof | 遵义医科大学 | 2020-06-19 | — | — | CN | claimed |
| CN-109810572-A | Inorganic nano material prints ink and its preparation method and application | 深圳TCL工业研究院有限公司 | 2019-05-28 | — | — | CN | claimed |
| US-20190010159-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE AND MUTANT EGFR | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-01-10 | — | — | US | claimed |
| EP-3398950-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE EGFR AND MUTATED EGFR | Precedo Pharmaceuticals Co., Ltd. (CN) | 2018-11-07 | — | — | EP | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| US-7122536-B2 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | PFIZER INC. (US) | 2006-10-17 | — | — | US | claimed |
| US-7015223-B1 | Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2006-03-21 | — | — | US | claimed |
| US-7015230-B1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2006-03-21 | — | — | US | claimed |
| WO-2001077079-A2 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-10-18 | — | — | WO | claimed |
| WO-2001077097-A2 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-10-18 | — | — | WO | claimed |
| WO-2001068605-A1 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED BENZENES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-09-20 | — | — | WO | claimed |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2001-08-30 | — | — | US | claimed |
| EP-1115695-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(N+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1115694-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC (TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018723-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000018724-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010159-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE AND MUTANT EGFR | EGFR, ERBB2, ERBB3 | CA3 4807/4885CA6 1553/4885CA5A 1887/4885 |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | CA3 4722/4885CA6 4791/4885CA5A 4440/4885 |
| US-10781214-B2 | Kinase inhibitor against wild-type and mutant EGFR | EGFR, ERBB2, ERBB3 | CA3 4707/4885CA6 1306/4885CA5A 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.